SLRN vs. AVBP, COGT, PAHC, RLAY, CDMO, SANA, TYRA, SEPN, CRON, and REPL
Should you be buying Acelyrin stock or one of its competitors? The main competitors of Acelyrin include ArriVent BioPharma (AVBP), Cogent Biosciences (COGT), Phibro Animal Health (PAHC), Relay Therapeutics (RLAY), Avid Bioservices (CDMO), Sana Biotechnology (SANA), Tyra Biosciences (TYRA), Septerna (SEPN), Cronos Group (CRON), and Replimune Group (REPL). These companies are all part of the "pharmaceutical products" industry.
Acelyrin vs.
Acelyrin (NASDAQ:SLRN) and ArriVent BioPharma (NASDAQ:AVBP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, earnings, community ranking, dividends, analyst recommendations and institutional ownership.
Acelyrin currently has a consensus target price of $9.60, indicating a potential upside of 382.41%. ArriVent BioPharma has a consensus target price of $36.80, indicating a potential upside of 50.76%. Given Acelyrin's higher probable upside, equities research analysts clearly believe Acelyrin is more favorable than ArriVent BioPharma.
ArriVent BioPharma's return on equity of -43.89% beat Acelyrin's return on equity.
Acelyrin and ArriVent BioPharma both received 16 outperform votes by MarketBeat users. However, 100.00% of users gave ArriVent BioPharma an outperform vote while only 55.17% of users gave Acelyrin an outperform vote.
87.3% of Acelyrin shares are held by institutional investors. Comparatively, 9.5% of ArriVent BioPharma shares are held by institutional investors. 13.6% of Acelyrin shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, ArriVent BioPharma had 2 more articles in the media than Acelyrin. MarketBeat recorded 3 mentions for ArriVent BioPharma and 1 mentions for Acelyrin. Acelyrin's average media sentiment score of 1.66 beat ArriVent BioPharma's score of 0.91 indicating that Acelyrin is being referred to more favorably in the media.
Summary
ArriVent BioPharma beats Acelyrin on 7 of the 11 factors compared between the two stocks.
Get Acelyrin News Delivered to You Automatically
Sign up to receive the latest news and ratings for SLRN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Acelyrin Competitors List
Related Companies and Tools
This page (NASDAQ:SLRN) was last updated on 1/21/2025 by MarketBeat.com Staff
Free SLRN Stock Alerts